search
Back to results

Carry-over Effects of Repetitively Applied Transcutaneous Spinal Cord Stimulation on Spasticity (SCS-CorE)

Primary Purpose

Spinal Cord Injuries, Spasticity, Muscle

Status
Withdrawn
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Stimulette r2x+
Sponsored by
Swiss Paraplegic Research, Nottwil
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injuries

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • motor and sensory incomplete spinal cord injury classified as grade C or D on the American Spinal Injury Association Impairment Scale
  • neurological level of spinal cord injury: third cervical to tenth thoracic segment
  • chronic condition (≥ 12 months post-spinal cord injury)
  • preserved segmental and cutaneo-muscular reflexes in the lower limbs
  • able to be verticalized for 6 minutes (with walking aids)
  • preserved joint mobility, no musculoskeletal diseases
  • spasticity (with/without antispasticity medication)
  • stable antispasmodic medication one month prior to as well as during study participation

Exclusion Criteria:

  • neuromuscular diseases, e.g., amyotrophic lateral sclerosis (ALS), Parkinson's disease, Guillain-Barré syndrome, muscular dystrophy
  • dermatological issues at the stimulation site
  • acute urinary tract infection at study entry
  • active implants (e.g., cardiac pacemaker, drug pump)
  • passive implants between the ninth thoracic level and the first lumbal level (e.g. metal screws/plates for surgical stabilization of spinal fractures)
  • malignant diseases
  • heart insufficiency
  • potential pregnancy (pregnancy test to be conducted as part of the first evaluation)

Sites / Locations

  • Swiss Paraplegic Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

daily stimulation

stimulation every other day

Arm Description

30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.

30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.

Outcomes

Primary Outcome Measures

Change in spasticity index
Spasticity index based on the Wartenberg pendulum test: For the pendulum test, subjects will be in a supported sitting position with the trunk reclined approximately 30°. The examiner will lift one leg to a horizontal position, release it, and let it oscillate passively until it stops. The pendulum test will be repeated three times on each side, separated by phases of relaxation. The spasticity index is calculated subtracting the knee angle of the initial horizontal leg position from the peak flexion angle of the first swing divided by the final knee resting angle. Scores ≥ 1 denote non-spastic conditions, and 0 extreme spasticity.

Secondary Outcome Measures

Change in numeric rating scale spasticity
The severity of spasticity is rated using a numeric rating scale from a minimum of 0 to a maximum of 10. Higher values represent worse outcome.
Change in Modified Ashworth Scale
The resistance to passive movement will be clinically graded according to the Modified Ashworth Scale. Individual scores from both legs will be summed (with a value of 1.5 for the 1+ scoring category) to result in a single Modified Ashworth Scale-sum score (0-96; 0, no increase in muscle tone) per assessment. Higher values represent worse outcome.
Change in adductor tone rating
5-point ordinal scale describing adductor tone during passive abduction (0: normal tone - 4: maximal tone). Higher values represent worse outcome.
Change in Penn Spasm Frequency Scale
5-point scale rating the frequency and severity of spasms (0: no spasms - 4: more than 10 spasms per hour). Higher values represent worse outcome.
Change in resistance of the lower limbs
Measure of the resistance of the lower limbs to manipulation performed by a robotic system (MotionMaker, SWORTEC SA). The MotionMaker measures torque (N) and power output (W).
Change in 6-minute walk test
distance in meters walked over a span of 6 minutes
Change in Walking Index for Spinal Cord Injury II Scale
21-point ordinal scale that rates the extent and nature of assistance (e.g., walker, crutches, cane, braces, physical assistance) required to complete the 10-m walk test (0: unable to complete the test - 20: ambulated without any assistance). Higher values represent better outcome.

Full Information

First Posted
January 22, 2019
Last Updated
March 14, 2023
Sponsor
Swiss Paraplegic Research, Nottwil
Collaborators
Medical University of Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT03815721
Brief Title
Carry-over Effects of Repetitively Applied Transcutaneous Spinal Cord Stimulation on Spasticity
Acronym
SCS-CorE
Official Title
Carry-over Effects of Repetitively Applied Transcutaneous Spinal Cord Stimulation on Spasticity and Residual Motor Control in Incomplete Spinal Cord Injured Individuals
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Decision of the 2 PI's
Study Start Date
January 7, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Swiss Paraplegic Research, Nottwil
Collaborators
Medical University of Vienna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Spinal cord injury is a devastating condition, causing substantial impairment of vital body functions caudal to the lesion. A major cause of disability stems from spasticity, a common secondary sequelae. Its various clinical manifestations include spasms, clonus, and resistance to passive movements, and often present a major hindrance in rehabilitation, further deteriorate residual motor performance, and negatively impact independence and quality of life. Despite its high prevalence, successful management of spasticity has remained difficult. Standard-of-care treatment modalities are often insufficient or bear the risk of undesirable side effects further accentuating paresis. Epidural stimulation of the lumbar spinal cord via implanted electrodes provides for an alternative approach. It works through modifying the dysregulated neural signal processing of spared spinal circuitry caudal to the injury. Its ameliorative effects on severe lower-limb spasticity have been repetitively reported. Yet, epidural spinal cord stimulation in motor disorders is still off-label, applied in relatively few patients only, also because of its invasive character, the time consuming testing phase for its effective application, and the lack of markers to identify responders in advance. With the development of transcutaneous spinal cord stimulation, a method became available to activate the same input structures to the lumbar spinal cord as with epidural stimulation and hence to induce similar neuromodulatory effects, yet non-invasively, using standard equipment available at rehabilitation centers. A recent proof-of-concept study has shown that a single 30-minute session of transcutaneous spinal cord stimulation controlled various clinical signs of spasticity and augmented residual motor control in spinal cord injured individuals for several hours beyond its application. Further, in one subject, the stimulation was repetitively applied for six weeks, resulting in cumulative therapeutic effects persisting for 10 days after its discontinuation. These observations strongly suggest that the stimulation can induce beneficial neuroplastic adaptations of spared spinal systems and their interaction with residual supraspinal control. The proposed research aims at studying the reproducibility of these findings in a statistically sound cohort of individuals with spinal cord injury and testing the applicability and acceptance of transcutaneous spinal cord stimulation as a home-based therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Spasticity, Muscle

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
daily stimulation
Arm Type
Experimental
Arm Description
30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
Arm Title
stimulation every other day
Arm Type
Experimental
Arm Description
30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
Intervention Type
Device
Intervention Name(s)
Stimulette r2x+
Intervention Description
device for repetitive transcutaneous spinal cord stimulation
Primary Outcome Measure Information:
Title
Change in spasticity index
Description
Spasticity index based on the Wartenberg pendulum test: For the pendulum test, subjects will be in a supported sitting position with the trunk reclined approximately 30°. The examiner will lift one leg to a horizontal position, release it, and let it oscillate passively until it stops. The pendulum test will be repeated three times on each side, separated by phases of relaxation. The spasticity index is calculated subtracting the knee angle of the initial horizontal leg position from the peak flexion angle of the first swing divided by the final knee resting angle. Scores ≥ 1 denote non-spastic conditions, and 0 extreme spasticity.
Time Frame
from day 1 to day 57
Secondary Outcome Measure Information:
Title
Change in numeric rating scale spasticity
Description
The severity of spasticity is rated using a numeric rating scale from a minimum of 0 to a maximum of 10. Higher values represent worse outcome.
Time Frame
day 1, 8, 29, 50 and 57
Title
Change in Modified Ashworth Scale
Description
The resistance to passive movement will be clinically graded according to the Modified Ashworth Scale. Individual scores from both legs will be summed (with a value of 1.5 for the 1+ scoring category) to result in a single Modified Ashworth Scale-sum score (0-96; 0, no increase in muscle tone) per assessment. Higher values represent worse outcome.
Time Frame
from day 1 to day 57
Title
Change in adductor tone rating
Description
5-point ordinal scale describing adductor tone during passive abduction (0: normal tone - 4: maximal tone). Higher values represent worse outcome.
Time Frame
from day 1 to day 57
Title
Change in Penn Spasm Frequency Scale
Description
5-point scale rating the frequency and severity of spasms (0: no spasms - 4: more than 10 spasms per hour). Higher values represent worse outcome.
Time Frame
from day 1 to day 57
Title
Change in resistance of the lower limbs
Description
Measure of the resistance of the lower limbs to manipulation performed by a robotic system (MotionMaker, SWORTEC SA). The MotionMaker measures torque (N) and power output (W).
Time Frame
from day 1 to day 57
Title
Change in 6-minute walk test
Description
distance in meters walked over a span of 6 minutes
Time Frame
from day 1 to day 57
Title
Change in Walking Index for Spinal Cord Injury II Scale
Description
21-point ordinal scale that rates the extent and nature of assistance (e.g., walker, crutches, cane, braces, physical assistance) required to complete the 10-m walk test (0: unable to complete the test - 20: ambulated without any assistance). Higher values represent better outcome.
Time Frame
from day 1 to day 57

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: motor and sensory incomplete spinal cord injury classified as grade C or D on the American Spinal Injury Association Impairment Scale neurological level of spinal cord injury: third cervical to tenth thoracic segment chronic condition (≥ 12 months post-spinal cord injury) preserved segmental and cutaneo-muscular reflexes in the lower limbs able to be verticalized for 6 minutes (with walking aids) preserved joint mobility, no musculoskeletal diseases spasticity (with/without antispasticity medication) stable antispasmodic medication one month prior to as well as during study participation Exclusion Criteria: neuromuscular diseases, e.g., amyotrophic lateral sclerosis (ALS), Parkinson's disease, Guillain-Barré syndrome, muscular dystrophy dermatological issues at the stimulation site acute urinary tract infection at study entry active implants (e.g., cardiac pacemaker, drug pump) passive implants between the ninth thoracic level and the first lumbal level (e.g. metal screws/plates for surgical stabilization of spinal fractures) malignant diseases heart insufficiency potential pregnancy (pregnancy test to be conducted as part of the first evaluation)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ursula Hofstötter
Organizational Affiliation
Medical University Vienna
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Angela Frotzler
Organizational Affiliation
Swiss Paraplegic Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Swiss Paraplegic Centre
City
Nottwil
State/Province
LU
ZIP/Postal Code
6207
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Carry-over Effects of Repetitively Applied Transcutaneous Spinal Cord Stimulation on Spasticity

We'll reach out to this number within 24 hrs